Marshall Wace’s AbCellera Biologics ABCL Stock Holding History

Marshall Wace’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$14.9M	Buy	1,902,191 +1,542,508	+429%	+$7.54M	0.01%	856
2026 Q1	$1.26M	Buy	+359,683	New	+$1.29M	﹤0.01%	2022
2025 Q4	–	Sell	-47,480	Closed	-$239K	–	2900
2025 Q3	$239K	Hold	47,480	–	–	﹤0.01%	2517
2025 Q2	$163K	Hold	47,480	–	–	﹤0.01%	2486
2025 Q1	$106K	Buy	+47,480	New	+$136K	﹤0.01%	2495
2023 Q1	–	Sell	-97,600	Closed	-$989K	–	2587
2022 Q4	$989K	Sell	97,600 -256,797	-72%	-$2.97M	﹤0.01%	2100
2022 Q3	$3.5M	Sell	354,397 -159,313	-31%	-$1.75M	0.01%	1641
2022 Q2	$5.47M	Buy	+513,710	New	+$4.35M	0.01%	1271
2021 Q4	–	Sell	-338,120	Closed	-$6.78M	–	3809
2021 Q3	$6.78M	Buy	338,120 +64,841	+24%	+$1.15M	0.03%	780
2021 Q2	$6.01M	Buy	273,279 +222,638	+440%	+$6.14M	0.03%	739
2021 Q1	$1.72M	Sell	50,641 -461,769	-90%	-$18.4M	0.01%	1398
2020 Q4	$20.6M	Buy	+512,410	New	+$23.4M	0.11%	186

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Marshall Wace's ABCL Position: Q2 2026 in Review

Marshall Wace increased its AbCellera Biologics (ABCL) stake by 429% in Q2 2026, buying an estimated $7.54M and bringing the position to 1,902,191 shares worth $14.9M. The position accounts for 0.01% of the portfolio, ranked #856.

Marshall Wace first reported a position in ABCL in Q4 2020 and has held it in 12 quarters since. The position peaked at $20.6M in Q4 2020. 151 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

Marshall Wace held 1,902,191 shares of AbCellera Biologics worth $14.9M as of Q2 2026.
Marshall Wace bought 1,542,508 AbCellera Biologics shares in Q2 2026, an estimated $7.54M.
AbCellera Biologics made up 0.01% of Marshall Wace's portfolio in Q2 2026, its #856 holding.
Marshall Wace first reported a position in AbCellera Biologics in Q4 2020 and has held it in 12 quarters since.
Marshall Wace's AbCellera Biologics position peaked at $20.6M in Q4 2020.
151 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.